

Cleansing Notice under section 708A of the Corporations Act 2001 (Cth) (“Corporations Act”)

BRISBANE, AUSTRALIA, 16 September 2026: AnteoTech Ltd (ASX: ADO) (**AnteoTech** or the **Company**) hereby provides notice to the ASX for the purpose of section 708A(5)(e) of the Corporations Act 2001 (Cth) (“Corporations Act”) that it has issued 5,386,569 fully paid ordinary shares (“Shares”) in the Company pursuant to the ASX Appendix 2A lodged today issuing shares to staff in relation to FY2026 performance outcomes under the Company’s Equity Incentive Plan and announced in the Appendix 3B, Proposed Issues of Securities, on the 1 September 2026.

The Company states pursuant to the provisions of section 708A(5)(e) of the Corporations Act that:

- the Shares were issued today without disclosure to investors under Part 6D.2 of the Corporations Act;
- this notice is being given under section 708A(5)(e) of the Corporations Act;
- as at the date of this notice, it has complied with
 - the relevant provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - Section 674 of the Corporations Act; and
- as at the date of this notice, there is no “excluded information”, as that term is defined in Sections 708A(7) and 708A(8) of the Corporations Act.

This announcement has been authorised for release by the Board of AnteoTech Ltd.

- ENDS -

Media and investor enquiries: on +61 7 3219 0085 or investors@anteotech.com

Company and Partnering enquiries: Merrill Gray, CEO/MD, on + 61 7 3219 0085

For further information, please check our website www.anteotech.com

About AnteoTech – (ASX: ADO)

AnteoTech is a supplier of advanced chemical and material solutions to the battery materials and life sciences markets. We leverage our market leading binding chemical platform technology to develop and commercialise solutions for our global customer base. From our patented high silicon anode cross linker product Anteo X™ to our ceramic coated separator product Anteo S™ and our Collector foil primer coating performance additive Anteo C through to our next-generation high silicon anode formulations Ultranode™ 70, 95 and X our Advanced Battery Technology business is applying its world-leading engineering expertise to address the growing demand for high performance, low cost, sustainable chemicals and materials within the global Lithium ion Battery market. Our Life Sciences business supplies advanced activation materials to leading developers and manufacturers of vaccines and diagnostic tests, through our AnteoBind™ suite of products. Our products deliver more sensitive and reproducible results and on incorporation in 'point of care' and other immunoassay diagnostic tests such as Chemiluminescence immunoassays (CLIA) and Enzyme-Linked Immunosorbent Assay (ELISA) plates, AnteoBind™ NXT enables faster, more reliable and more accurate test results wherever they are needed.

AnteoTech – Social Media Policy

AnteoTech is committed to communicating with the investment community through all available channels. Whilst ASX remains the prime channel for market sensitive news, investors and other interested parties are encouraged to follow AnteoTech on LinkedIn. Subscribe to AnteoTech Latest News emails – visit our website at www.anteotech.com and subscribe to receive our email alert service.

Forward Looking Statements

This Announcement may contain forward-looking statements, including estimates, projections and other forward-looking information (Estimates and Projections). Forward-looking statements can generally be identified by the use of forward-looking words such as “expect”, “anticipate”, “likely”, “intend”, “should”, “could”, “may”, “predict”, “plan”, “propose”, “will”, “believe”, “forecast”, “estimate”, “target”, “outlook”, “guidance” and other similar expressions within the meaning of securities laws of applicable jurisdictions and include, but are not limited to, indications of, or guidance or outlook on, future earnings or financial position or performance of AnteoTech. The Estimates and Projections are based on information available to AnteoTech as at the date of the Announcement, are based upon management’s current expectations, estimates, projections, assumptions and beliefs in regard to future events in respect to AnteoTech’s business and the industry in which it operates which may in time prove to be false, inaccurate or incorrect. The Estimates and Projections are provided as a general guide and should not be relied upon as an indication or guarantee of future performance. The bases for these statements are subject to risks and uncertainties that might be out of control of AnteoTech and may cause actual results to differ from the Announcement. No representation, warranty, or guarantee, whether express or implied, is made or given by AnteoTech in relation to any Estimates and Projections, the accuracy, reliability, or reasonableness of the assumptions on which the Estimates and Projections are based, or the process of formulating any Estimates and Projections, including that any Estimates and Projections contained in this Announcement will be achieved. AnteoTech takes no responsibility to make changes to these statements to reflect change of events or circumstances after the release.



ANTEOTECH LTD ACN 070 028 625

Unit 4, 26 Brandl St
Brisbane Technology Park
Eight Mile Plains QLD 4113 Australia

11: +61 7 3219 0085
IS! contact@anteotech.com
G) anteotech.com

